Overview

Desmopressin in Cardiac Surgery

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products. Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.
Phase:
Phase 4
Details
Lead Sponsor:
Università Vita-Salute San Raffaele
Treatments:
Deamino Arginine Vasopressin